Trial reportRevista de la Facultad de Ciencias Medicas (Cordoba, Argentina)2021
Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
Trial report in Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis.Frontiers in medicine · 2022Pooled it
- Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.Frontiers in immunology · 2023Trial
- Design, Conduct, and Analysis of Externally Controlled Trials.JAMA network open · 2025Article
- Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022.Heliyon · 2024Article
- Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023Review
- Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding.Scientific reports · 2023Article
- Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.Frontiers in pharmacology · 2023Review
- Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review.BMJ medicine · 2023Article
- Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.Biomedicines · 2022Review
- Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19.iScience · 2022Article
- A Peek into Pandora's Box: COVID-19 and Neurodegeneration.Brain sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. Methods: In this prospective, multicenter, single arm (compared with a historical control), add-on, experimental phase 2 study, ruxolitinib 5 mg BID was added to standard of care in COVID-19 patients. Main objective was to determine efficacy and safety of ruxolitinib in patients with COVID-19-related SARS. Results: Even though we could not show a significant reduction of COVID-19 pneumonia patients requiring intensive care unit admission and mechanical ventilation (primary endpoint), a trend to a lower mortality rate in critical ill patients receiving ruxolitinib was reported. Administered ruxolitinib dose had to be increased according to protocol in 32% of patients, without additional toxicity. Conclusion: Side effects profile was manageable, and no direct organ injury was caused by the study drug. Ruxolitinib had a fast anti-inflammatory effect, and one-third of patients felt well immediately after starting treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.